Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
Rheumatol Ther . 2019 Dec;6(4):503-520. doi: 10.1007/s40744-019-00167-6. Epub 2019 Aug 13.
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Rheumatol Ther . 2019 Dec;6(4):503-520. doi: 10.1007/s40744-019-00167-6. Epub 2019 Aug 13.
JAMA 2019 322(4):315-325
Arthritis Rheumatol 2019 DOI: 10.1002/art.41032
Ann Rheum Dis 2019 DOI: 10.1136/annrheumdis-2019-215764
Please click the links below to go to the CSF review of each paper
Ann Rheum Dis. 2019 Feb;78(2):171-178. DOI 10.1136/annrheumdis-2018-213271
J Rheumatol. 2019 Jan;46(1):7-18. DOI: 10.3899/jrheum.171361
Rheumatology 2018;57:1423–1431 DOI: 10.1093/rheumatology/key121
Drug Safety 2018 Jul;41(7):645–53
Lancet 2018;391:2513–24